POS1290 REGISTER-BASED DATA ON DIET AND ALCOHOL CONSUMPTION: A NEW WAY TO COLLECT DATA ON LIFESTYLE FACTORS IN RHEUMATOLOGY

Résumé fourni par la source

Background: Lifestyle habits have become increasingly important to take into consideration in the management of rheumatic diseases, although the role of diet and alcohol remain unclear. Clinical registers collect information on a large number of unselected patients and can become important sources of data on lifestyle factors. Objectives: To describe the information the Swedish Rheumatology Quality register (SRQ) has acquired on diet and alcohol consumption since implementation of their data collection. Methods: In the Swedish Rheumatology Quality Register, SRQ, data on clinical variables from patients with rheumatological diseases is collected with the purpose to analyze and ensure high-quality and equal care. The data may also be used for research, and due to the high quality and coverage (87% for rheumatoid arthritis) it has been a key source for hundreds of research projects in Sweden and internationally. The register includes clinical and laboratory variables, as well as patient reported outcome measures. In addition, the register collects information on lifestyle factors, like smoking habits, physical activity, and, since April 2023, on diet and alcohol consumption. Alcohol consumption data are based on AUDIT-C (The Alcohol Use Disorders Identification Test) [1], including three questions on quantity and frequency of alcohol consumption, adding up to a score from 0 to 12 with a higher score indicating higher consumption. A score of ≥5 for men and ≥4 for women is considered as an unhealthy lifestyle. Questions on diet are based on a dietary index developed by the National Board of Health and Welfare which is commonly used in national surveys and clinical practice. The four questions give a score from 0 to 12, where a higher index indicates a more healthy diet, and a score of ≤4 represent an unhealthy diet. Results: Of a total of 102 867 active patients in SRQ on the 31 st December 2024, 34 662 patients had reported data on diet and 28 408 on alcohol consumption during the 21 months of data collection. The distribution of diagnoses in the SRQ was reflected among the responders with majority of the patients having rheumatoid arthritis. 11674 and 9144 patients had longitudinal data (i.e. more than one record) for diet and alcohol respectively. To perform studies on the influence of diet and alcohol consumption on treatment efficacy and retention, we need to have information at start of treatment. By defining a window of ±30 days from start of methotrexate (MTX) and biological or targeted synthetic disease modifying antirheumatic drugs (b/tsDMARDs), we observed that 1997 and 1617 patients had information at start of MTX and 1951 and 1566 at start of b/tsDMARD, for diet and alcohol respectively. Across diagnoses, more RA patient reported at start of MTX then at start of b/tsDMARD, but the opposite was observed for the other diseases. Overall, most of the patients (64%) had a moderately healthy diet (score between 5 and 8), while 15% had indications of an unhealthy diet (score below 5). Almost no variation can be seen across diagnoses. Regarding alcohol, 13% had a score that indicates unhealthy habits. A low variation could be observed across diagnoses, with PsA patients having the highest percentage of unhealthy alcohol habits. Figure 1Histograms of number of patients with reported information on diet and alcohol in the Swedish Rheumatology Quality register and pie charts for the distribution of diet and alcohol categories Conclusion: In less than 2 years SRQ was able to collect a large amount of data on diet and alcohol. Although this information has been collected with clinical care as the main focus, the importance of this data for research purposes is undeniable. We hope that this data will help to scientifically understand the role of diet and alcohol in the management of rheumatic conditions. REFERENCES: [1] Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumptionquestions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory CareQuality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. Arch InternMed. 1998 Sep 14;158(16):1789–9 Table 1Numbers of patients with reported information on diet and alcohol in the Swedish Rheumatology Quality register.AllRAPsASpA/ASSLEGCAOther diseasesDietN patients with ≥1 record34 66217531591351616222125223N patients with ≥2 record11674645317841558156581665At start of MTX treatment19971317303731110283At start of b/tsDMARD treatment19519143573661212290Diet categories (%):Score 0-4 (unhealthy)15.4614.2716.9817.8114.157.0815.93Score 5-863.9464.5563.7662.5563.9966.9863.35Score 9-12 (healthy)20.6021.1919.2619.6521.8625.9420.72AlcoholN patients with ≥1 record28 40814046500543964891674305N patients with ≥2 record9144495914321271115421325At start of MTX treatment161710682556157221At start of b/tsDMARD treatment156671428331489238Alcohol categories (%):≥5 for men, ≥4 for women (unhealthy)13.3712.2814.9513.9913.0913.7714.45<5 for men, <4 for women86.6387.7285.0586.0186.9186.2385.55RA=rheumatoid arthritis, PsA=psoriatic arthritis, SpA=spondyloarthritis, AS=ankylosing spondylitis, SLE=systemic lupus erythematosus, GCA=giant cell arteritis Acknowledgements: The authors thank all patients providing information to the Swedish Rheumatology Quality register. Disclosure of Interests: Daniela Di Giuseppe: None declared, Malin Regardt: None declared, Susanne Pettersson AstraZeneca, Novartis, Pfizer, Vifor CSL, Simon Steiger: None declared, Marie-Louise Karlsson: None declared, Björn Sundström: None declared, Lotta Ljung has through Karolinska University Hospital signed present or earlier agreements with Abbvie, Amgen, Eli Lilly, Alfasigma, Novartis, Pfizer, Sanofi, SObi, UCB, Jansen&Jansen, BMS, GSK, Otsuka, AstraZeneca, in the role of PI for the Swedish Rheumatology Quality Register, SRQ. All agreements and payments are/were handled within the University Hospital. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.